tag:blogger.com,1999:blog-7857054149675424609.post2308313820954117925..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Alternate Use of Two SiRNAs for Chronic RNAi TherapeuticsDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-7857054149675424609.post-31064665274911090322008-05-18T15:54:00.000+00:002008-05-18T15:54:00.000+00:00Thanks for the question, Martin. I've tried to ad...Thanks for the question, Martin. I've tried to address the issue in the May 17 entry. Hope that helps,<BR/>Dirk.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-65542200359023431142008-05-15T22:14:00.000+00:002008-05-15T22:14:00.000+00:00Hi Dirkexcuse an off-topic question and one that d...Hi Dirk<BR/><BR/>excuse an off-topic question and one that demonstrates my scientific ignorance but perhaps you will educate me on the following:<BR/><BR/>Delivery of RNAi trigger into the right tissue is clearly the limiting factor for therapeutical applications of RNAi (and I understand that SNALPs with the ability to deliver siRNA into the liver and certain other issues represent a significantAnonymousnoreply@blogger.com